Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 5.0 | 4.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 1.93 | 2.25 |
NAV | ₹432.40 | ₹294.79 |
Fund Started | 04 Jun 1999 | 01 Aug 2005 |
Fund Size | ₹4026.55 Cr | ₹1146.13 Cr |
Exit Load | Exit load of 0.50% if redeemed within 15 days | Exit load of 1% if redeemed within 30 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 11.57% | 11.77% |
3 Year | 26.71% | 25.59% |
5 Year | 20.22% | 18.83% |
1 Year
3 Year
5 Year
Equity | 97.60% | 97.66% |
Cash | 2.33% | 2.34% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.44% |
Divi's Laboratories Ltd. | 7.21% |
Max Healthcare Institute Ltd. | 6.50% |
Cipla Ltd. | 4.63% |
Lonza Group Ag | 4.09% |
Lupin Ltd. | 4.02% |
Gland Pharma Ltd. | 3.59% |
Mankind Pharma Ltd. | 3.57% |
Acutaas Chemicals Ltd. | 3.30% |
Krishna Institute of Medical Sciences Ltd | 3.26% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 9.84% |
Cipla Ltd. | 5.43% |
Ajanta Pharma Ltd. | 4.80% |
Lupin Ltd. | 4.29% |
Procter & Gamble Health Ltd. | 4.13% |
Dr. Reddy's Laboratories Ltd. | 3.99% |
Glenmark Pharmaceuticals Ltd. | 3.54% |
Fortis Healthcare Ltd. | 3.48% |
Apollo Hospitals Enterprise Ltd. | 3.47% |
Gland Pharma Ltd. | 3.01% |
Name | Tanmaya Desai | Kamal Gada |
Start Date | 27 Jun 2011 | 02 May 2022 |
Name
Start Date
Description | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 04 Jun 1999 | 01 Aug 2005 |
Description
Launch Date